Discuss the adequacy of India's drug-price regulatory framework in reducing out-of-pocket expenditure on catastrophic illnesses.

In India, a six-month course of some modern cancer drugs can cost more than several years of income [1]. The Drugs (Prices Control) Order (DPCO), 2013 eases such bills but is only partly adequate against catastrophic out-of-pocket expenditure (OOPE).

Where the framework helps

• Ceiling prices: NPPA fixes ceilings for essential (NLEM) medicines in DPCO's First Schedule [2].
• Para 19 power: trade margins on 137 non-scheduled anti-cancer drugs are capped at 30% of MRP from 9 November 2026 [3].
• Scale: expected savings are ₹3,540.38 crore a year [4], expanding a 2019 pilot that cut MRPs of 526 brands by up to 90% [5].
• Insurance gap: PM-JAY covers only inpatient care, while OOPE is mostly on outpatient care and medicines [6]; lower MRPs act on this share.

Where it remains inadequate

• Narrow tool: a margin cap trims the trader's share, not the manufacturer's price; WHO notes cancer drug prices may bear little link to research and production costs [7].
• Temporary basis: DPCO permits margin capping only for a limited period [8]; in August 2026 a Standing Committee flagged the absence of a permanent framework [9].
• Weak enforcement: State Drug Controllers enforce the order [3], yet NPPA keeps no state-wise overcharging record [10], and overcharged dues remain stuck in litigation [9].
• Savings unproven: the figure is an estimate; patients already receiving discounts, or covered by schemes, gain less.
• Residual cost: modern therapies may still exceed PM-JAY's ₹5 lakh family cover [11], and AMRIT pharmacies offered 289 cancer medicines through only 217 outlets (June 2025) [12].

Way forward

• Write margin rules into DPCO, specifying entry, duration and review [8].
• Add tendering, price transparency and early biosimilar entry for the costliest drugs, as WHO advises [13].
• Examine outpatient cancer-medicine cover under PM-JAY; place AMRIT and Jan Aushadhi pharmacies in empanelled hospitals [6].
• Publish state-wise overcharging, recovery and stock data, since percentage caps may favour costlier brands.

Thus, India's framework has lowered medicine prices but not the full burden of catastrophic illness. Permanent margin rules, procurement tools and outpatient cover together can convert episodic relief into lasting financial protection, advancing the right to health under Article 21 and universal health coverage (SDG 3.8).